Bank of America Corp DE Makes New $8.57 Million Investment in Beta Bionics, Inc. $BBNX

Key Points

• Bank of America initiated an $8.57 million position in Beta Bionics, purchasing 546,650 shares and owning about 1.22% of the company. Several other institutional investors also recently acquired stakes.
• Analyst sentiment is broadly positive: Beta Bionics has a “Moderate Buy” consensus rating and an average price target of $22.91, with Wells Fargo and Truist setting $28 targets.
• Despite institutional support, the company remains unprofitable and faces reported legal and FDA-related concerns. Recent insider sales were primarily attributed to tax withholding, while the stock opened at $21.51 and has a one-year range of $8.80 to $32.71.

Bank of America Corp DE bought a new position in shares of Beta Bionics, Inc. (NASDAQ:BBNX - Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund bought 546,650 shares of the company's stock, valued at approximately $8,566,000. Bank of America Corp DE owned approximately 1.22% of Beta Bionics at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Caitong International Asset Management Co. Ltd grew its position in shares of Beta Bionics by 1,075.7% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,987 shares of the company's stock worth $61,000 after buying an additional 1,818 shares in the last quarter. Legal & General Group Plc purchased a new position in Beta Bionics in the second quarter worth approximately $62,000. The Manufacturers Life Insurance Company acquired a new position in Beta Bionics during the 2nd quarter worth approximately $172,000. ProShare Advisors LLC acquired a new position in Beta Bionics during the 4th quarter worth approximately $217,000. Finally, Ieq Capital LLC purchased a new stake in shares of Beta Bionics in the 2nd quarter valued at approximately $229,000.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on BBNX. Wells Fargo & Company initiated coverage on shares of Beta Bionics in a report on Wednesday. They issued an "overweight" rating and a $28.00 price objective on the stock. Leerink Partners upped their price objective on Beta Bionics from $24.00 to $27.00 and gave the stock an "outperform" rating in a research report on Monday, September 14th. Robert W. Baird increased their price objective on Beta Bionics from $14.00 to $16.00 and gave the company a "neutral" rating in a report on Tuesday, September 15th. Bank of America boosted their target price on Beta Bionics from $18.00 to $20.00 and gave the stock a "neutral" rating in a research note on Tuesday, September 15th. Finally, Truist Financial upped their price target on Beta Bionics from $23.00 to $28.00 and gave the company a "buy" rating in a report on Thursday. Eight equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, Beta Bionics currently has a consensus rating of "Moderate Buy" and an average price target of $22.91.

Insider Activity

In related news, insider Mike Mensinger sold 4,375 shares of the firm's stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $19.11, for a total transaction of $83,606.25. Following the transaction, the insider owned 180,040 shares of the company's stock, valued at $3,440,564.40. This trade represents a 2.37% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Stephen Feider sold 6,675 shares of the business's stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $19.11, for a total value of $127,559.25. Following the completion of the transaction, the chief financial officer owned 159,378 shares in the company, valued at $3,045,713.58. This trade represents a 4.02% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders have sold 102,223 shares of company stock valued at $1,983,398. Insiders own 5.30% of the company's stock.

Key Beta Bionics News

Here are the key news stories impacting Beta Bionics this week:

• Positive Sentiment: Truist Financial raised its price target on Beta Bionics to $28 from $23 and maintained a “Buy” rating, implying meaningful upside from recent trading levels. Wells Fargo also initiated coverage with an “Overweight” rating and a $28 target, while other analysts have recently raised their targets. Truist Financial rating
• Neutral Sentiment: Multiple law firms publicized a securities class action against Beta Bionics on behalf of investors who purchased shares between July 30, 2025, and February 24, 2026. The lead-plaintiff deadline is November 3, 2026; the repeated notices are mostly informational but increase attention on the company’s legal situation. Kaplan Fox class action notice
• Negative Sentiment: The lawsuits allege that Beta Bionics failed to adequately disclose FDA concerns, including a 2025 Form 483 and more than 18,000 iLet-related complaints. The allegations link later disclosures about FDA compliance and device safety to a sharp share-price decline. They have not been proven, but could create financial, operational and reputational uncertainty. BFA Law BBNX investor alert
• Negative Sentiment: Director Christy Jones sold 6,430 shares for approximately $147,890, reducing her position by about 24.7%. The sale occurred under a pre-arranged Rule 10b5-1 plan, which makes it a less definitive bearish signal, but it nevertheless adds to investor caution. SEC insider sale filing

Beta Bionics Stock Performance

BBNX opened at $21.51 on Friday. The business's 50-day simple moving average is $18.17 and its 200-day simple moving average is $14.42. The stock has a market capitalization of $967.73 million, a P/E ratio of -13.04 and a beta of 3.37. Beta Bionics, Inc. has a one year low of $8.80 and a one year high of $32.71.

Beta Bionics (NASDAQ:BBNX - Get Free Report) last released its quarterly earnings results on Wednesday, July 29th. The company reported ($0.53) EPS for the quarter, topping the consensus estimate of ($0.62) by $0.09. Beta Bionics had a negative return on equity of 26.30% and a negative net margin of 61.31%.The company had revenue of $32.01 million for the quarter. On average, equities research analysts forecast that Beta Bionics, Inc. will post -2.06 EPS for the current fiscal year.

Beta Bionics Company Profile

Beta Bionics, Inc is a medical technology company focused on developing automated insulin-delivery systems for people with diabetes. Its principal product is the iLet Bionic Pancreas, an automated insulin-delivery system designed to simplify diabetes management by using continuous glucose monitoring data to adjust insulin dosing with limited user input.

The iLet Bionic Pancreas received clearance from the U.S. Food and Drug Administration in 2023 for use by people with type 1 diabetes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.